I-Mab Biopharma and MorphoSys have begun dosing patients in a late-stage study to assess the safety and efficacy of MorphoSys' investigational antibody MOR202 in combination with Revlimid, or lenalidomide, and dexamethasone to treat relapsed or refractory multiple myeloma. The study is being conducted in Taiwan, and its results will be used to support the filing of a biologics license application in China.
Dosing initiated in late-stage trial for combo therapy in myeloma
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.